DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the BIOCON LIMITED. (BIOCON) share price today?

BIOCON LIMITED. (BIOCON) is trading at ₹437.2 on the NSE, down 0.79% on the day. Source: DocStoX.

What is the PE ratio of BIOCON LIMITED.?

BIOCON LIMITED. has a price-to-earnings (PE) ratio of 183.7 in the Healthcare sector.

What is the market capitalisation of BIOCON LIMITED.?

BIOCON LIMITED. has a market capitalisation of approximately ₹70,332 crore.

BIOCON LIMITED.

F&O

BIOCON·NSE·Healthcare

₹437.20▼ -3.50 (-0.79%)

Healthcare · Pharmaceuticals

A steady, established business

NIFTY 200NIFTY 500NIFTY MIDCAP 150

Day₹432.80

₹444.45

52W₹331

₹44791%

Open

₹444.40

High

₹444.45

Low

₹432.80

Prev Close

₹440.70

Volume

88.11L

VWAP

₹436.78

Snapshot

Key fundamentals

Market Cap

₹70,332 Cr

P/E Ratio

183.70Expensive

P/B Ratio

1.99

EPS

₹2.38

Book Value

₹210.00

ROE

1.40%Weak

ROCE

4.00%Weak

Dividend Yield

0.12%

Debt / Equity

0.45Moderate

Face Value

₹5.00

52W High

₹447.15

52W Low

₹331.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹164

▼ 62.5%downside

Trading at ₹437 — 63% above our estimate

BearFair valueBull

₹106₹164₹189

/100

Business quality — Watch the fundamentals

Growth 30Profitability 0Efficiency 0Valuation 39

Plain English

Our view

A steady, established business
Low debt relative to equity
Weak returns on equity (1%)

Strengths

Low debt relative to equity

Risks

Weak returns on equity (1%)
Expensive — trades at 184× earnings
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

1% ROE fading to 13% over ~3 yrs, on ₹210 book

₹180

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹106

Analyst target

No analyst coverage

—

Blended fair value₹164

What the numbers say

Investment thesis

Bull case

Low debt relative to equity

Bear case

Weak returns on equity (1%)
Expensive — trades at 184× earnings
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

183.7Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

1.4%Weak

Above 15% is considered healthy for Indian equities

ROCE

4.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.45Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹70,332 Cr

P/B

1.99

EPS

₹2.38

Div Yield

0.12%

What changed

Recent changes

Foreign investors+0.6% stake last quarter
Domestic institutions-0.7% stake last quarter
Promoters-0.23% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 183.7×

Growth

Steady

+15% rev CAGR

Profitability

Modest

1.4% ROE

Financial health

Comfortable

D/E 0.45

Momentum

N/A

No technicals

Today

Trading activity

Delivery %60.0%

Turnover₹38486.15L Cr

Trades61,583

VWAP₹436.78

Face value₹5.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+14.8%

+18.8%

10Y

+17.6%

Profit

-16.9%

-15.3%

10Y

-4.9%

EPS

-14.8%

-17.4%

10Y

-6.4%

Profile

Cons

Company has low interest coverage ratio.
Company has a low return on equity of 3.51% over last 3 years.
Company might be capitalizing the interest cost
Dividend payout has been low at 10.9% of profits over last 3 years
Promoter holding has decreased over last 3 years: -16.0%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Promoters trimmed their stake by 0.23 pts; foreign investors bought 0.64 pts; domestic institutions reduced 0.70 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

45%

Promoter

Promoters

44.7%-0.23

Public

23.8%+0.35

FII / FPI

8.2%+0.64

DII

23.3%-0.70

Total shareholders

3,92,509+5,916 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter44.68%

FII8.16%

DII23.31%

Public23.75%

Others0.10%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)

F&O

BIOCON LIMITED. valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

BIOCON LIMITED. peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED

Compare BIOCON LIMITED. with peers

BIOCON LIMITED. vs SUN PHARMACEUTICAL IND L BIOCON LIMITED. vs DIVI S LABORATORIES LTD BIOCON LIMITED. vs TORRENT PHARMACEUTICALS L BIOCON LIMITED. vs APOLLO HOSPITALS ENTER. L BIOCON LIMITED. vs ZYDUS LIFESCIENCES LTD BIOCON LIMITED. vs CIPLA LTD

BIOCON LIMITED.

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

F&O

BIOCON LIMITED. valuation & research

BIOCON LIMITED. peers in Healthcare

Compare BIOCON LIMITED. with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Cons

Ownership breakdown

Ownership over time

Frequently asked questions